Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs第四季度每股收益美元（0.37）超過預期（0.38），銷售額爲26.2萬美元，低於預期的990.00萬美元
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 428.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $262.00 thousand which missed the analyst consensus estimate of $990.00 thousand by 73.54 percent.
Orchestra BioMed Hldgs（納斯達克股票代碼：OBIO）公佈的季度虧損爲每股0.37美元，比分析師共識估計的美元（0.38美元）高出2.63個百分點。這比去年同期每股虧損0.07美元（0.07）下降了428.57％。該公司公佈的季度銷售額爲26.2萬美元，比分析師普遍預期的990,000美元低73.54％。